Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ALPHAMAB ONCOLOGY
康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT
APPOINTMENT OF CHIEF FINANCIAL OFFICER

This announcement is made by Alphamab Oncology (the "**Company**," together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce the appointment of Mr. David NG (吳嘉俊) ("**Mr. Ng**") as the chief financial officer of the Company. Mr. Ng will be primarily responsible for the Group's capital markets strategy, investor relations and industry competitive analysis.

The biographical details of Mr. Ng are set out below:

Mr. Ng has extensive experience in capital markets, securities research, investor relations, and investment and financing management. Prior to joining the Group, he served as Head of Investor Relations and Capital Strategies at HUTCHMED (China) Limited (和黃醫藥(中國)有限公司), a company listed on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (stock code: 13) and was recognized in the Extel's Asia Executive Team survey for Best IR Program and Best IR Professional. Previously, Mr. Ng served as chief financial officer of MEDx Translational Medicine Research (Suzhou) Co., Ltd. (邁傑轉化醫學研究(蘇州)有限公司), a private company specializing in companion diagnostics. Earlier in his career, he also accumulated over 20 years of experience in sell-side equity research and held senior positions at UBS, Morgan Stanley, Bank of China International and Paradigm Capital.

Mr. Ng is a CFA charterholder and holds a Master of Business Administration degree and a Bachelor of Science degree in Pharmaceutical Science from the University of British Columbia, Canada.

The Board hereby announces that Mr. Fei WANG (王飛) ("**Mr. Wang**") has tendered his resignation as the chief financial officer of the Company due to his other work commitments. Mr. Wang has confirmed that he has no disagreement with the Company and there are no matters that need to be brought to the attention of the Stock Exchange and the shareholders of the Company in connection with his resignation.

The Company would like to take this opportunity to express its appreciation for the valuable contributions of Mr. Wang towards the Company during his tenure of service and warmly welcome Mr. Ng for his new position.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, November 12, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.